nach oben

Journal of Neuro-Oncology

Erschienen in:

01.09.2008 | Invited Manuscript

Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults

verfasst von: John Buatti, Timothy C. Ryken, Mark C. Smith, Penny Sneed, John H. Suh, Minesh Mehta, Jeffrey J. Olson

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Excerpt

Radiation therapy is recommended for the treatment of newly diagnosed malignant glioma in adults. Treatment schemes should include dosage of up to 60 Gy given in 2 Gy daily fractions that includes the enhancing area. …

Neuro-oncology Disease Site Group et al (2004) Radiotherapy for newly diagnosed malignant glioma in adults. Practice Guideline Report 9-3

Shapiro WR, Young DF (1976) Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol 33(7):494–550PubMed

Walker MD et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333–343PubMed

Walker MD et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303(23):1323–1329

Kristiansen K et al (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4):649–652PubMedCrossRef

Sandberg-Wollheim M et al (1991) A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1):22–29PubMedCrossRef

Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273PubMedCrossRef

Andersen AP (1978) Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 17(6):475–484 PubMed

Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64(4):769–774PubMed

10 .

Nelson DF et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma–possible advantage observed at 72.0 Gy in 1.2 Gy B·I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25(2):193–207PubMed

11.

Chang CH et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52(6):997–1007PubMedCrossRef

12.

Nelson DF et al (1988) Combined modality approach to treatment of malignant gliomas—reevaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988(6):279–284

13.

Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731 PubMed

14.

Lee S et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88PubMed

15.

Massey V, Wallner K (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398PubMed

16.

Wallner K et al (1989) Patterns of failure following treatment for glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMed

17.

Shapiro WR et al (1989) Randomized trial of three chemotherapy regimens, two radiotherapy regimens, two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71(1):1–9PubMed

18.

Kita M et al (1989) Radiotherapy of malignant glioma–prospective randomized clinical study of whole brain vs. local irradiation. Gan No Rinsho 35(11):1289–1294PubMed

19.

Phillips C et al (2003) A randomized trial comparing 35 Gy in ten fractions with 60 Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 68(1):23–26PubMedCrossRef

20.

Prados MD et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49(1):71–77PubMed

21.

Deutsch M et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. International Int J Rad Oncol Biol Phys 16(6):1389–1396

22.

Ludgate CM et al (1988) Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Rad Oncol Biol Phys 15(5):1091–1095

23.

Shin KH et al (1985) Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report. Cancer 56(4):758–760PubMedCrossRef

24.

Fulton DS et al (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10:1709–1712PubMed

25.

Shin KH, Muller PJ, Geggie PH (1983) Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer 52(11):2040–2043PubMedCrossRef

26.

Payne DG et al (1982) Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 50(11):2301–2306PubMedCrossRef

27.

Stuschke M, Thames HD (1997) Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37(2):259–267PubMed

28.

Kleinberg L et al (1997) Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Rad Oncol Biol Phys 38(1):31–36

29.

Bauman GS et al (1994) A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Rad Oncol Biol Phys 29(4):835–839

30.

Sultanem K et al (2004) The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58(1):247–252PubMedCrossRef

31.

Roa W et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22(9):1583–1588PubMedCrossRef

32.

Hulshof MC et al (2000) Hypofractionation in glioblastoma multiforme. Radiother Oncol 54(2):143–148PubMedCrossRef

33.

Ford JM et al (1997) A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 9(1):20–24

34.

Hoegler DB, Davey P (1997) A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neuro-oncol 33(3):201–204CrossRef

35.

Slotman BJ et al (1996) Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Rad Oncol Biol Phys 34(4):895–898

36.

Thomas R et al (1994) Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 33(2):113–116PubMedCrossRef

37.

Glinski B (1993) Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neuro-oncol 16(2):167–172CrossRef

38.

Brada M et al (1999) Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Rad Oncol Biol Phys 43(2):287–292

39.

Werner-Wasik M et al (1996) Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 77(8):1535–1543PubMedCrossRef

40.

Horiot JC et al (1988) European organization for research on treatment of cancer trials using radiotherapy with multiple fractions per day. A 1978–1987 survey. Front Radiat Ther Oncol 22:149–161PubMed

41.

Keim H et al (1987) Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiotherapy and Oncology : Radiother Oncol 9(1):21–26PubMedCrossRef

42.

Simpson WJ, Platts ME (1976) Fractionation study in the treatment of glioblastoma multiforme. International Int J Radiat Oncol Biol Phys 1(7–8):639–644PubMed

43.

Wen PY et al (1994) Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73(12):3029–3036PubMedCrossRef

44.

Sneed PK et al (1998) Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40(2):287–295PubMed

45.

Sneed PK et al (1995) Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 36(5):898–903 discussion 903–904PubMedCrossRef

46.

Chang CN et al (2003) High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes. J Neurooncol 61(1):45–55PubMedCrossRef

47.

Koot RW et al (2000) Brachytherapy: results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 88(12):2796–2802PubMedCrossRef

48.

Videtic GM et al (2001) Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 51(4):963–968PubMed

49.

Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6(3):227–235PubMedCrossRef

50.

Laperriere NJ et al (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41(5):1005–1011PubMed

51.

Selker RG et al (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51(2):343–355 discussion 355–357PubMedCrossRef

52.

Chang CN et al (2003) High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes. J Neurooncol 61(1):45–55 PubMedCrossRef

53.

Mayr MT et al (2002) Results of interstitial brachytherapy for malignant brain tumors. Int J Oncol 21(4): 817–823 PubMed

54.

Curran WJ Jr et al (1993) Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyper-fractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11(5):857–862PubMed

55.

Lustig RA, Scott CB, Curran WJ (2004) Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies? Am J Clin Oncol 27(5):516–521PubMedCrossRef

56.

Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853–860PubMed

57.

Masciopinto JE et al (1995) Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 82(4):530–535PubMed

58.

Gannett D et al (1995) Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys 33(2):461–468PubMed

59.

Buatti JM et al (1995) Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int J Radiat Oncol Biol Phys 32(1):205–210PubMed

60.

Mehta MP et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30(3):541-549PubMed

61.

Kondziolka D et al (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41(4):776–783 discussion 783–785PubMedCrossRef

62.

Larson DA et al (1996) Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys 36(5):1045–1053PubMed

63.

Sarkaria JN et al (1995) Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 32(4): 931–941PubMed

64.

Cho KH et al (2004) Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme. Technol Cancer Res Treat 3(1):41–49

65.

Nwokedi EC et al (2002) Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50(1):41–46 discussion 46–47PubMedCrossRef

66.

Shrieve DC et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90(1):72–77PubMedCrossRef

Titel: Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults
verfasst von: John Buatti
Timothy C. Ryken
Mark C. Smith
Penny Sneed
John H. Suh
Minesh Mehta
Jeffrey J. Olson
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2008
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9617-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Neuroradiological assessment of newly diagnosed glioblastoma

Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme

Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery

Diagnosis of malignant glioma: role of neuropathology

Guidelines for the treatment of newly diagnosed glioblastoma: introduction